1. Home
  2. SRE vs TAK Comparison

SRE vs TAK Comparison

Compare SRE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBA Sempra

SRE

DBA Sempra

N/A

Current Price

$76.60

Market Cap

56.3B

Sector

Utilities

ML Signal

N/A

Logo Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)

TAK

Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)

N/A

Current Price

$21.82

Market Cap

69.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRE
TAK
Founded
1998
1781
Country
United States
Japan
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.3B
69.1B
IPO Year
2008
2007

Fundamental Metrics

Financial Performance
Metric
SRE
TAK
Price
$76.60
$21.82
Analyst Decision
Buy
Strong Buy
Analyst Count
21
3
Target Price
★ $96.44
$24.48
AVG Volume (30 Days)
★ 3.7M
3.1M
Earning Date
11-05-2026
10-29-2026
Dividend Yield
★ 3.45%
1.12%
EPS Growth
N/A
★ N/A
EPS
★ 1.58
N/A
Revenue
★ $13,702,000,000.00
N/A
Revenue This Year
N/A
$4.79
Revenue Next Year
N/A
$2.44
P/E Ratio
$48.28
★ $41.25
Revenue Growth
★ 3.92
N/A
52 Week Low
$76.21
$14.16
52 Week High
$101.04
$21.86

Technical Indicators

Market Signals
Indicator
SRE
TAK
Relative Strength Index (RSI) 31.67 69.50
Support Level $76.21 $17.66
Resistance Level $87.12 N/A
Average True Range (ATR) 1.56 0.33
MACD -0.53 -0.01
Stochastic Oscillator 2.03 82.22

Price Performance

Historical Comparison
SRE
TAK

About SRE DBA Sempra

Sempra serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure Partners, 25% owned by Sempra, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.

About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.

Share on Social Networks: